Meisoindigo is primarily used in the treatment of chronic myeloid leukemia (CML). It functions by inhibiting the proliferation of leukemia cells, helping to manage and control the disease. The compound is known for its ability to induce differentiation and apoptosis in cancer cells, making it a valuable component in chemotherapy regimens. Additionally, it has shown efficacy in reducing the symptoms and progression of certain types of cancer, particularly those involving abnormal cell growth. Meisoindigo is often used in combination with other therapeutic agents to enhance its effectiveness and improve patient outcomes. Its application in oncology continues to be explored for potential benefits in treating other forms of cancer as well.